secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0000950170-24-121068
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q3 net loss $26.4M; FDA lifts partial clinical hold on zorevunersen; STK-002 Phase 1 delayed
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $269.2M as of Sep 30, 2024.
- Net loss Q3 2024 $26.4M ($0.47/shr) vs $24.5M ($0.55/shr) Q3 2023.
- Revenue from Acadia collaboration $4.9M in Q3 2024 vs $3.3M in Q3 2023.
- FDA removed partial clinical hold on zorevunersen; plans to provide Phase 3 data and regulatory update by year-end.
- Phase 1 study of STK-002 (ADOA) delayed to focus on zorevunersen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024121068/0000950170-24-121068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024121068/stok-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer